A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease
Abstract
The CDP571 was effective for corticosteroid-sparing at week 16 but not week 10, and was well-tolerated in patients with corticosteroid-dependent Crohn's disease.
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
research support
non-u.s. gov't
adult
female
male
middle aged
Drug Administration Schedule
Clinical Trial
Randomized Controlled Trial
Antibodies
Monoclonal / therapeutic use*
Double-Blind Method
severity of illness index
Gastrointestinal Agents / therapeutic use*
monoclonal / adverse effects
crohn disease / drug therapy*
anti-inflammatory agents
non-steroidal / therapeutic use*
phase ii
anti-inflammatory agents / adverse effects
quality of life
tumor necrosis factor-alpha / antagonists & inhibitors
anti-inflammatory agents / administration & dosage
prednisolone / administration & dosage
crohn disease / pathology
pmid:15709987
doi:10.1111/j.1365-2036.2005.02336.x
b g feagan
w j sandborn
s b hanauer
budesonide / administration & dosage
Access
Citation
ID:
269350
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
269350
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet